The Future of Obesity Pharmacotherapy: From Single Agonists to Combination Approaches

A Decade of Transformation

Obesity drug treatment has changed more in the past five years than in the five decades before. For most of modern medicine, the drugs available for obesity barely worked, were hard to tolerate or carried safety problems that got them pulled from the market. Potent incretin-based therapies have changed what a drug can achieve, and raised expectations for what comes next.

The Progression of Receptor Targeting

The trajectory is clear in retrospect. Liraglutide, a GLP-1 receptor agonist approved for obesity in 2014, produced approximately 8% mean weight loss. Semaglutide 2.4 mg, a more potent and longer-acting GLP-1 agonist, pushed this to roughly 15%. Tirzepatide, a dual GIP/GLP-1 agonist, reached approximately 22%. And retatrutide, adding glucagon receptor agonism to create a triple agonist, showed 24% in Phase 2 and has now demonstrated 28.7% in Phase 3 (TRIUMPH-4, 68 weeks, 12 mg dose).

Each step added a receptor target and raised efficacy a bit further. That raises a basic question, though: is activating more receptors always better, or are we reaching diminishing returns?

The Glucagon Component: What It Adds

Retatrutide’s distinguishing feature is its glucagon receptor agonism. While GLP-1 and GIP primarily reduce energy intake through appetite suppression and metabolic signaling, glucagon receptor activation is thought to increase energy expenditure. Preclinical data from Coskun et al. showed that the triple combination produced greater weight loss and improvements in hepatic steatosis than dual agonism alone.

TRIUMPH-4 Phase 3 data (December 2025) confirmed that this carries over strongly to humans, with 28.7% weight loss at 12 mg over 68 weeks. It is an important step in how obesity drugs work. Obesity treatment has long focused almost entirely on cutting calorie intake. A therapy that meaningfully raises energy expenditure works on the other side of the energy balance, which may lead to longer-lasting weight loss and better metabolic outcomes.

Combination Strategies: CagriSema and Beyond

An alternative approach to multi-receptor agonism is combination therapy using separate agents. CagriSema, developed by Novo Nordisk, combines semaglutide (a GLP-1 agonist) with cagrilintide (a long-acting amylin analog). By targeting complementary appetite-regulating pathways, this combination produced 22.7% weight loss at 68 weeks in the REDEFINE 1 trial among people who stayed on treatment (20.4% counting everyone). Novo Nordisk filed it with the FDA in December 2025.

Combining separate drugs has its own advantages: each component’s dose can be adjusted separately, and components can be added or removed depending on how the patient responds and tolerates them. It also adds complexity in manufacturing, administration and cost.

Other pipeline candidates are exploring additional mechanisms:

• Survodutide (Boehringer Ingelheim): a dual GLP-1/glucagon agonist, testing a different ratio of receptor activation than retatrutide.
• Orforglipron (Eli Lilly): a small-molecule oral GLP-1 agonist, which could greatly widen access by removing the need for injections.
• Bimagrumab and related myostatin/activin inhibitors: aimed at preserving or building lean mass during weight loss, since large weight loss includes muscle as well as fat.

The Oral Frontier

One of the biggest coming developments is oral incretin therapy reaching maturity. Right now, all potent GLP-1 class drugs are injected under the skin, which creates barriers: fear of needles, cold-chain storage and the systems needed to deliver the drug.

Oral semaglutide (Rybelsus) exists, but at lower doses with smaller weight loss. Higher-dose oral versions and entirely new oral molecules like orforglipron could make obesity treatment as easy as taking a daily pill. If retatrutide or a similar triple agonist could one day be given by mouth, the effect on obesity treatment worldwide would be large.

Update, October 2026: the FDA approved a higher-dose oral semaglutide for weight management, the Wegovy pill (25 mg), on December 22, 2025, and orforglipron, as Foundayo, on April 1, 2026.

Muscle Preservation: The Next Frontier

A growing concern in the field is what kind of weight is lost during treatment. Approximately 25-40% of weight lost with GLP-1 class drugs may be lean mass, including muscle. While this ratio is comparable to diet-induced weight loss, the absolute amount of muscle lost at 20-25% total body weight reduction is clinically significant, particularly for older adults at risk of sarcopenia.

This has sparked interest in combining weight loss drugs with anabolic therapies that target muscle. Whether such combinations prove practical and effective will be an important question for the next generation of obesity treatment.

Where Retatrutide Fits

Retatrutide now has a clear, data-backed place in this changing field. It is the most advanced triple-agonist candidate, and its pivotal Phase 3 results have confirmed its potency: 28.7% weight loss at 12 mg in TRIUMPH-4, 28.3% in TRIUMPH-1, and 20.8% and 22.6% in the diabetes and cardiovascular-disease populations of TRIUMPH-2 and TRIUMPH-3 (July 2026). Eli Lilly says it plans to file for approval no later than the first quarter of 2027; by our estimate, a decision could come in late 2027 with priority review or around the first quarter of 2028 with standard review. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA); Lilly is contesting that in court and has not said which pathway it will use (the FDA ruling). Its mix of strong weight loss, higher energy expenditure and joint benefits (74-76% pain reduction in knee OA) makes it a fit for patients with severe obesity and metabolic conditions. Dysesthesia, a dose-dependent side effect (20.9% at 12 mg in TRIUMPH-4), will weigh on its balance of benefits and risks. The full TRIUMPH-3 publication, the head-to-head TRIUMPH-5 trial against tirzepatide and the TRIUMPH-Outcomes cardiovascular trial will further define its clinical role.

It is unlikely to be the last word. The field is moving fast, and the next decade will probably bring new advances in receptor targeting, delivery and combinations. The most important change is not any single molecule. It is the wider recognition that obesity is a chronic, treatable disease that deserves the same rigorous drug treatment as hypertension, diabetes and hyperlipidemia.

A Balanced Perspective

Enthusiasm should be tempered by realism. Long-term safety data for newer agents remain limited. Weight regain after discontinuation is a consistent finding across the class. Cost and access remain major barriers globally. And pharmacotherapy alone cannot address the environmental and systemic factors that drive obesity prevalence.

Still, the direction is clear. Effective obesity drugs have arrived, and retatrutide is one of the most promising, though certainly not the last.